PAPER Zhang T, Kim BM, Lee TH
SEARCH RESULTS
270360 RESULTS
PAPER Gao Y, Wang Y, Lei H, Xu Z, Li S, Yu H, Xie J, Zhang Z, Liu G, Zhang Y, Zheng J, Wang JZ
Correction: A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau.
Transl Neurodegener. 2024 Jan 11;13(1):5. PubMed.PAPER Sharif A, Mamo J, Lam V, Al-Salami H, Mooranian A, Watts GF, Clarnette R, Luna G, Takechi R
The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases.
Transl Neurodegener. 2024 Jan 22;13(1):6. PubMed.PAPER Liu Y, Tan Y, Zhang Z, Yi M, Zhu L, Peng W
The interaction between ageing and Alzheimer's disease: insights from the hallmarks of ageing.
Transl Neurodegener. 2024 Jan 23;13(1):7. PubMed.PAPER Lin CP, Frigerio I, Bol JG, Bouwman MM, Wesseling AJ, Dahl MJ, Rozemuller AJ, van der Werf YD, Pouwels PJ, van de Berg WD, Jonkman LE
Microstructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer's disease and Parkinson's disease.
Transl Neurodegener. 2024 Feb 9;13(1):9. PubMed.PAPER Rim C, You MJ, Nahm M, Kwon MS
Emerging role of senescent microglia in brain aging-related neurodegenerative diseases.
Transl Neurodegener. 2024 Feb 20;13(1):10. PubMed.PAPER Leandrou E, Chalatsa I, Anagnostou D, Machalia C, Semitekolou M, Filippa V, Makridakis M, Vlahou A, Anastasiadou E, Vekrellis K, Emmanouilidou E
α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Cav3.2 calcium signaling in astrocytes.
Transl Neurodegener. 2024 Feb 21;13(1):11. PubMed.PAPER Ma YY, Li X, Yu JT, Wang YJ
Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside.
Transl Neurodegener. 2024 Feb 27;13(1):12. PubMed.PAPER Lubben N, Brynildsen JK, Webb CM, Li HL, Leyns CE, Changolkar L, Zhang B, Meymand ES, O'Reilly M, Madaj Z, DeWeerd D, Fell MJ, Lee VM, Bassett DS, Henderson MX
LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression.
Transl Neurodegener. 2024 Mar 4;13(1):13. PubMed.PAPER Bigi A, Fani G, Bessi V, Napolitano L, Bagnoli S, Ingannato A, Neri L, Cascella R, Matteini P, Sorbi S, Nacmias B, Cecchi C, Chiti F
Putative novel CSF biomarkers of Alzheimer's disease based on the novel concept of generic protein misfolding and proteotoxicity: the PRAMA cohort.
Transl Neurodegener. 2024 Mar 8;13(1):14. PubMed.PAPER Laferrière F, Sabatier L, Claverol S, De Giorgi F, Ichas F
Biases in α-synuclein immuno-quantitation: a core problem for basic and ancillary studies of Parkinson's disease and multiple system atrophy.
Transl Neurodegener. 2024 Mar 25;13(1):15. PubMed.PAPER Li W, Li JY
Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration.
Transl Neurodegener. 2024 Mar 26;13(1):16. PubMed.PAPER Moutinho D, Mendes VM, Caula A, Madeira SC, Baldeiras I, Guerreiro M, Cardoso S, Gobom J, Zetterberg H, Santana I, De Mendonça A, Aidos H, Manadas B
Pathophysiological subtypes of mild cognitive impairment due to Alzheimer's disease identified by CSF proteomics.
Transl Neurodegener. 2024 Apr 9;13(1):19. PubMed.PAPER Liu Y, Yan D, Yang L, Chen X, Hu C, Chen M
Stathmin 2 is a potential treatment target for TDP-43 proteinopathy in amyotrophic lateral sclerosis.
Transl Neurodegener. 2024 Apr 11;13(1):20. PubMed.PAPER Gee MS, Kwon E, Song MH, Jeon SH, Kim N, Lee JK, Koo T
CRISPR base editing-mediated correction of a tau mutation rescues cognitive decline in a mouse model of tauopathy.
Transl Neurodegener. 2024 Apr 12;13(1):21. PubMed.Current Filters
- TYPE: Paper x